EXACT Sciences Corp. (EXAS)
Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
EXAS SEC Filing Email Alerts Service
Company Name: |
EXACT Sciences Corp. |
Website: |
www.exactsciences.com |
Sector: |
Biotechnology |
Number of ETFs Holding EXAS: |
53 |
Total Market Value Held by ETFs: |
$1.43B |
Total Market Capitalization: |
$10.77B |
% of Market Cap. Held by ETFs: |
13.24% |
|
|
May 3, 2024 8:00 AM Eastern
Strong Buy (3.68 out of 4)
67th percentile
|
|